Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
−2.35USD
−98.43 MUSD
34.16 MUSD
18.71 M
About Foghorn Therapeutics Inc.
Sector
Industry
CEO
Adrian Gottschalk
Website
Headquarters
Cambridge
Employees (FY)
116
Founded
2015
FIGI
BBG00HFZPB88
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where FHTX is featured.
Frequently Asked Questions
The current price of FHTX is 5.32 USD — it has increased by 5.25% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Foghorn Therapeutics Inc. stocks are traded under the ticker FHTX.
Foghorn Therapeutics Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
FHTX stock is 6.39% volatile and has beta coefficient of 3.03. Check out the list of the most volatile stocks — is Foghorn Therapeutics Inc. there?
FHTX earnings for the last quarter are −0.34 USD per share, whereas the estimation was −0.70 USD resulting in a 51.43% surprise. The estimated earnings for the next quarter are −0.74 USD per share. See more details about Foghorn Therapeutics Inc. earnings.
Foghorn Therapeutics Inc. revenue for the last quarter amounts to 17.48 M USD despite the estimated figure of 4.58 M USD. In the next quarter revenue is expected to reach 4.54 M USD.
Yes, you can track Foghorn Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
FHTX stock has fallen by 14.27% compared to the previous week, the month change is a 18.98% fall, over the last year Foghorn Therapeutics Inc. has showed a 3.19% decrease.
FHTX net income for the last quarter is −24.11 M USD, while the quarter before that showed −14.35 M USD of net income which accounts for −68.04% change. Track more Foghorn Therapeutics Inc. financial stats to get the full picture.
Today Foghorn Therapeutics Inc. has the market capitalization of 214.96 M, it has increased by 2.98% over the last week.
No, FHTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FHTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Foghorn Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 116.00 employees. See our rating of the largest employees — is Foghorn Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Foghorn Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Foghorn Therapeutics Inc. stock shows the sell signal. See more of Foghorn Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Foghorn Therapeutics Inc. future price: according to them, FHTX price has a max estimate of 20.00 USD and a min estimate of 13.00 USD. Read a more detailed Foghorn Therapeutics Inc. forecast: see what analysts think of Foghorn Therapeutics Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Foghorn Therapeutics Inc. EBITDA is −101.97 M USD, and current EBITDA margin is −290.57%. See more stats in Foghorn Therapeutics Inc. financial statements.